Crossmark

RBBP4 downregulation increases the sensitivity of A549 and HeLa cells to cisplatin by inhibiting cyclin D1 expression

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2025.100637

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Zeng, Zhiyu https://orcid.org/0009-0004-6294-0927
Mai, Meiqing https://orcid.org/0009-0004-5702-0667
Wang, Dandan https://orcid.org/0009-0005-8671-4542
Ouyang, Jie https://orcid.org/0009-0005-6003-4071
Chen, Zhiru https://orcid.org/0009-0000-6241-8937
Zhong, Jingjing https://orcid.org/0000-0003-4939-877X
Rao, Jinjun https://orcid.org/0009-0005-4699-5968
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-03-31
More Information

This article is maintained by: Elsevier

Article Title: RBBP4 downregulation increases the sensitivity of A549 and HeLa cells to cisplatin by inhibiting cyclin D1 expression

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2025.100637

Content Type: article

Copyright: © 2025 HCFMUSP. Published by Elsevier España, S.L.U.